Jobs / United States / Glaxosmithkline LLC
Head, Oncology Clinical Development - ADCs
Glaxosmithkline LLC · 🇺🇸 5 Locations
Sponsorship verdict
Sponsorship possible
One solid signal, not two — worth applying, and worth asking about sponsorship early.
- Employer is on a government sponsor recordThe US Department of Labor certified 39 H-1B/E-3 labor condition applications for this employer between Oct 2025 and Jun 2026 (latest Jun 2026) — the step every H-1B hire needs first. USCIS also records 15 H-1B approvals in FY2023. Source: LCA disclosure data (US Department of Labor (OFLC)).
- The posting doesn’t mention sponsorshipSilence isn’t a refusal — ask the recruiter before investing much time.
- No salary bar for this routeH-1B has no fixed salary bar: the employer must pay at least the prevailing wage for the role and area. Cap-subject employers enter a lottery weighted by wage level. Source: https://www.federalregister.gov/documents/2025/12/29/2025-23853/weighted-selection-process-for-registrants-and-petitioners-seeking-to-file-cap-subject-h-1b, rules effective 2026-02-27.
- What Glaxosmithkline LLC paid sponsored hires in similar roles1 certified filing for “Sr Manager - Oncology Commercial Analytics, Multiple Myeloma” (Data Scientists) in PA: $135k–$135k, median $135k. Most were filed at wage level III (100%) — 3 lottery entries, ≈46% projected selection odds for cap-subject employers. Source: US Department of Labor LCA disclosure data (Oct 2025 – Jun 2026).
- Confirmed live todayWhen a source last listed this job as open.
US H-1B: cap-subject employers enter a lottery weighted by wage level — Level I gets 1 entry, Level IV gets 4 (DHS projected selection odds ≈15% at Level I to ≈61% at Level IV). Universities and non-profit research employers are cap-exempt. The $100,000 fee for new petitions from abroad is currently blocked by a court order (appeal pending).
A verdict summarises public evidence; it is not legal advice and never a guarantee — the employer and the immigration authority decide. Sign in to factor in where you can already work.
Or apply yourself on the official page →
Sponsor Radar — Glaxosmithkline LLC
The US Department of Labor certified 39 H-1B/E-3 labor condition applications for this employer between Oct 2025 and Jun 2026 (latest Jun 2026) — the step every H-1B hire needs first. USCIS also records 15 H-1B approvals in FY2023. Source: LCA disclosure data (US Department of Labor (OFLC)).
Past sponsorship or register membership never guarantees sponsorship for this vacancy or for you. Full Sponsor Radar for Glaxosmithkline LLC →
About the role
For candidates seeking to be located at our Stevenage site, this role will temporarily be based at Stevenage. However, the Company plans to relocate its offices to Cambridge, UK. The location of this role will therefore subsequently change to Cambridge, UK in accordance with timelines to be set by the Company. The relocation is currently proposed to take effect by early 2029 . The Head, Oncology Clinical Development- ADCs, will report to the SVP, Head of Oncology Clinical Development. The role holder will be accountable for the design and implementation of the clinical development strategy across a particular asset across multiple tumor types spanning early- and late-phase development. This includes the strategic clinical positioning of the asset, combinations, and associated clinical development plans. This role requires an experienced, cross-matrix senior leader capable of implementing and executing an integrated clinical strategy in support of the successful clinical development, translational research, regulatory filing and initial market launch of a growing portfolio of innovative and transformational Oncology agents. Key Responsibilities & Accountabilities: Clinical Development Strategy & Portfolio Leadership • Accountable for end‑to‑end clinical development of an MOA-focused, multi-tumor asset, including registrational trials, regulatory approval, and initial market launch, ensuring scientific rigor, speed, and quality of execution. • Shape and drive the scientific and clinical development strategy for the asset and disease areas, aligned with Oncology Tumor Team strategy and broader Oncology portfolio priorities. • Evaluate, champion, and enable the use of novel approaches (e.g., AI/ML, innovative trial designs, external and real‑world data sources) where they add clear scientific, operational, or decision‑making value to clinical development. Program Oversight, Governance & Visibility • Provide oversight and connectedness across the asset program, maintaining visibility to progress, risks, dependencies, and trade‑offs across the Oncology portfolio. • Serve as the default senior clinical representative at key governance forums (e.g., DRB, PIB, program and portfolio governance) for the asset, ensuring strong clinical leadership, continuity, and high‑quality decision‑making. • Represent the Oncology Clinical Development organization internally and externally, including presenting at high‑impact forums such as congress all‑hands, senior leadership reviews, and advisory boards. • Lead scientific advisory boards and other external engagements to inform asset strategy, competitive positioning, and portfolio decisions, incorporating emerging science and external expert insight. Cross‑Functional Leadership & Connector Role • Act as a senior connector across functions, partnering closely with Oncology Research, Precision Medicine/Companion Diagnostics, Medical Affairs, Commercial, Competitive Intelligence, and Global Product Strategy to drive integrated development and lifecycle planning. • Drive asset alignment across research, development, and commercialization planning, and ensuring cohesive execution against shared objectives. • Build and sustain strong internal and external partnerships to accelerate decision‑making, resolve complexity, and optimize development outcomes in a matrixed environment. Culture & Capability Building • Foster a culture of empowerment, scientific excellence, inclusion, and collaboration, aligned with OneOncology values, while modeling strong, visible leadership. • Actively remove organizational barriers and enable teams to operate effectively and autonomously within a complex, global matrix environment. Standards, Processes & Continuous Improvement • Contribute to the establishment